Top

Published in:

01-06-2006 | Original Article

Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract

Authors: Yasuyoshi Miyata, Kojiro Ohba, Shigeru Kanda, Koichiro Nomata, Jiro Eguchi, Tomayoshi Hayashi, Hiroshi Kanetake

Published in: Virchows Archiv | Issue 6/2006

Abstract

The prostaglandin E2 receptor, EP4 receptor (EP4R), plays an important role in the development of transitional cell carcinoma of the upper urinary tract (TCC-UUT). However, the clinical significance of other EP receptors (EP1R–3R) is not clear. Furthermore, the pathological function of EP receptors in such patients is not understood. In the present study, we examined the expression of EP1R–3R in 101 TCC-UUT tissues by immunohistochemistry. Furthermore, we defined the relationship between cyclooxygenase (COX)-2 and EP receptor expression, proliferation index (PI), microvessel density (MVD), and expression of metalloproteinase-2 (MMP-2), urokinase-type plasminogen activator (uPA), and exon v6 containing CD44 isoform (CD44 v6) by multivariate analysis. The expression of EP1R, EP2R, and EP3R was positive in 20 (19.8%), 26 (25.7%), and 14 (13.9%) tumor samples, respectively. Expression of these receptors was not associated with pathological findings or survival. COX-2 and EP4R were independently associated with MVD and MMP-2, and uPA or PI and MMP-2, respectively. Other EP receptors were not influenced by any factors. Our results suggest that EP1R–3R play a minimal role in cancer progression in patients with TCC-UUT. On the other hand, EP4R regulates tumor progression via cancer cell proliferation and MMP-2, distinct from COX-2.

Arber N, Levin B (2005) Chemoprevention of colorectal cancer: ready for routine use? Recent Results Cancer Res 166:213–230PubMed

Asano T, Shoda J, Ueda T, Kawamoto T, Todoroki T, Shimonishi M, Tanabe T, Sugimoto Y, Ichikawa A, Mutoh M, Tanaka N, Miwa M (2002) Expression of cyclooxygenase-1 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res 8:1157–1167PubMed

Braun JR, DuBois RN (2005) COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23:2840–2855CrossRefPubMed

Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, Hla T (2004) Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101:591–596PubMedCrossRef

Chen Y, Hugh-Fulfold M (2000) Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer. Br J Cancer 82:2000–2006CrossRefPubMed

Coleman RA, Smith WL, Narumiya S (1994) International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46:205–229PubMed

Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, Huang M, Pold M, Batra RK, Dubinett SM (2001) Non-small cell cancer cyclooxygenase-dependent invasion is mediated by CD44. J Biol Chem 276:20809–20812CrossRefPubMed

Dohadwala M, Bartra RK, Luo J, Lin Y, Krysan K, Põld M, Sharma S, Dubinett SM (2002) Autocrine/paracrine PGE2 production by non-small cell lung cancer cells regulates MMP-2 and CD44 in COC-2 dependent invasion. J Biol Chem 52:50828–50833CrossRef

Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063–1073PubMed

10.

Eschwege P, Ferlicot S, Droupy S, Ba N, Conti M, Loric S, Coindard G, Denis I, Ferretti L, Cornelius A, Legrand A, Bedossa P, Benoit G, Jardin A, Scardiono P (2003) A histopathologic investigation of PGE(2) pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder. Eur Urol 44:435–441CrossRefPubMed

11.

Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J (2003) Prostaglandin E₂ protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in APC^min/+ mice. Cancer Res 62:403–408

12.

Hong RL, Pu YS, Hsieh TS, Chu JS, Lee WJ (1996) Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol 153:2025–2028CrossRef

13.

Inoue K, Kamada M, Salton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CF, Shuin T (2002) The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 8:1863–1870PubMed

14.

Jabbour HN, Milne SA, Williams AR, Anderson RA, Boddy SC (2001) Expression of COX-2 and PGE synthase and synthesis of PGE(2) in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer 85:1023–1031CrossRefPubMed

15.

Kawamori T, Uchiya N, Nakatsugi S, Watanabe K, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Sugimura T, Wakabayashi K (2002) Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP1 antagonists, on breast cancer development. Carcinogenesis 22:2001–2004CrossRef

16.

Kinugasa Y, Hatori M, Ito H, Kurihara Y, Ito D, Nagumo M (2004) Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis 21:737–745CrossRefPubMed

17.

Kömhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y, Koch MO, Shapper SB, Breyer MD (2000) Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 157:29–35PubMed

18.

Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, Dubinett SM (2005) Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 65:6275–6281PubMedCrossRef

19.

Li G, Yang T, Yan J (2002) Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun 299:886–890CrossRefPubMed

20.

Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306–1311PubMed

21.

Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H (2003) Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 9:1741–1749PubMed

22.

Miyata Y, Shigeru K, Nomata K, Hayashida Y, Kanetake H (2004) Expression of metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 and -2 in transitional cells carcinoma of the upper urinary tract: correlation with tumor stage and survival. Urology 63:602–608CrossRefPubMed

23.

Miyata Y, Shigeru K, Nomata K, Eguchi J, Kanetake H (2005) Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract. J Urol 173:56–60PubMedCrossRef

24.

Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KNM, Masferrer JL, Woerner Snyder PW, Koki AT (1999) Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59:987–990PubMed

25.

Munkarah A, Ali-Fehmi R (2005) COX-2: a protein with an active role in gynecological cancers. Curr Opin Obstet Gynecol 17:49–53PubMed

26.

Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T, Wakabayshi K (2002) Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res 62:28–32PubMed

27.

Nakanishi K, Kawai T, Torikata C, Aurues T, Ikeda T (1998) Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma. Cancer 82:724–732CrossRefPubMed

28.

Nakanishi K, Kawai T, Sato H, Aida S, Kasamatsu H, Aurues T, Ikeda T (2000) Expression of matrix metalloproteinase-2 (MMP-2) and of membrane-type-1matrix metalloproteinase (MT1-MMP) in transitional cell carcinoma of the upper urinary tract. Hum Pathol 31:193–200CrossRefPubMed

29.

Rigas B, Goldman IS, Levine L (1993) Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122:518–523PubMed

30.

Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP, Jabbour HN (2001) Cyclooxygenase-2 expression and prostaglandin E2 synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 86:2243–2249CrossRefPubMed

31.

Sheng H, Shao J, Morrow JD, Beauchamp RD, Dubois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E₂ in human colon cancer cells. Cancer Res 58:326–362

32.

Sheng H, Shao J, Washington MK, Dubois RN (2001) Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276:75–81

33.

Toma V, Hauri D, Schmid U, Ackermann D, Maurer R, Alund G, Knönagel H, Rist M, Gasser TC, Sauter G, Roth J (1999) Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol 155:1427–1432PubMed

34.

Wendum D, Masliah J, Trugnan G, Flejou JF (2004) Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch 445:327–333CrossRefPubMed

35.

Yano T, Zissel G, Muller-Qernheim J, Shin SJ, Satoh H, Ichikawa T (2002) Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett 518:154–158CrossRefPubMed

36.

Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, Subbaramaiah K, Dannenberg AJ (2001) Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 7:3971–3976PubMed

37.

Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215:1–20CrossRefPubMed

38.

Zweifel BS, Davis TW, Ornberg RL, Masferrer JL (2002) Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E₂ in human head and neck xenograft tumors. Cancer Res 62:6706–6711PubMed

Title: Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract
Authors: Yasuyoshi Miyata
Kojiro Ohba
Shigeru Kanda
Koichiro Nomata
Jiro Eguchi
Tomayoshi Hayashi
Hiroshi Kanetake
Publication date: 01-06-2006
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 6/2006
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-006-0198-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2006

Deregulation of HMGA2 in an aggressive angiomyxoma with t(11;12)(q23;q15)

Up-regulation of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase were coupled with that of type I procollagen in granulation tissue response after the onset of aortic dissection

Esophageal squamous cell carcinoma with entirely intramural growth pattern

Monoallelic deletion of the p53 gene through chromosomal translocation in a small cell osteosarcoma

Malignant clear-cell myomelanocytic tumor of broad ligament—a case report

Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M. Pathological findings in a patient with Fabry disease, who died after 2.5 years of enzyme replacement. Virchows Arch. 2005 Nov 29; 1–7